Table 1.
Incidence and prevalence of NMOSD across the world.
| Authors, Year | Country | Number of Cases | Incidence (95% CI) (per Million per Year) | Prevalence (95% CI) (per 100,000) |
|---|---|---|---|---|
| Rivera et al., 2008 [54] | Mexico | 34 | 0.20 (0.05–0.35) | 1 |
| Cabrera-Gómez et al., 2009 [56] | Cuba | 58 | 0.44 (0.3–0.62) | 0.43 (0.29–0.61) |
| Asgari et al., 2011 [55] | Denmark | 42 | 4 (3.0–5.4) | 4.41 (3.1–5.7) |
| Aboul Enein et al., 2011 [57] | Austria | 71 | 0.54 (0.01–0.03) | 0.71 (0.17–0.96) |
| Cossburn et al., 2012 [58] | UK | 14 | NA | 1.96 (1.22–2.97) |
| Houzen et al., 2012 [59] | Japan | 3 | 0.8 (0.3–1.6) | 0.72 (0.31–1.42) |
| Jacob et al., 2013 [60] | UK | 13 | 0.8 (0.3–1.6) | 0.72 (0.31–1.42) |
| Etemadifar et al., 2014 [61] | Iran | 95 | NA | 1.95 (1.62–2.23) |
| Pandit et al., 2014 [62] | India | 11 | NA | 2.6 |
| Kashipazha et al., 2015 [63] | Iran | 51 | NA | 0.8 (0.54–1.06) |
| Flanagan et al., 2016 [53] | USA | 6 | 0.7 (0.0–2.1) | 3.9 (0.8–7.1) |
| Martinique | 39 | 7.3 (4.1–10.1) | 10.0 (6.8–13.2) | |
| van Pelt et al., 2016 [64] | Netherlands | 1.2 | NA | |
| Houzen et al., 2017 [65] | Japan | 14 | NA | 4.1 (2.2–6.9) |
| Hor et al., 2017 [66] | Malaysia | 14 | NA | 1.99 (1.09–3.35) |
| Bukhari et al., 2017 [67] | ANZ | 81 | 0.37 (0.36–0.38) | 0.7 (0.66–0.74) |
| Sepulveda et al., 2017 [68] | Spain | 74 | 0.63 (0.45–0.8) | 0.89 (0.87–0.91) |
| Holroyd et al., 2018 [69] | United Arab Emirates | 10 | 0.59 | 0.34 |
NMOSD: neuromyelitis optica spectrum disorders; NA: not available; ANZ: Australia and New Zealand.